June 12, 2024 – Page 8 – Goldea Capital

Accolade to Announce Fiscal First Quarter 2025 Financial Results

Written by Customer Service on June 12, 2024. Posted in Public Companies.

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad6356ede4b179553cca22ec02b2f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a live audio webcast that will be available online at http://ir.accolade.com. Replay: A replay of the call will be available for one year via webcast...

cBrain Signs Proof of Concept in Nigeria

Written by Customer Service on June 12, 2024. Posted in Public Companies.

Press Release no. 06/2024 cBrain Signs Proof of Concept in Nigeria Copenhagen, June 12, 2024 cBrain (NASDAQ: CBRAIN) has signed an agreement with the Ministry of Innovation, Science and Technology in Nigeria to deliver a Proof of Concept (PoC) project. The purpose of the PoC project is to deliver an F2-based solution, which demonstrates secure and transparent government procurement processes from planning and approval to filing and auditing, across multiple government agencies. Government contracts involve sensitive information, and using F2 for digitizing processes offers an effective approach to support transparent, efficient, and secure government procurement. The F2 platform represents a new generation of Commercial-off-the-Shelf (COTS) products, complete, fully integrated, and built for government. Out-of-the-box, F2 offers all...

Navigator Gas Announces Pricing of Upsized Secondary Public Offering by Selling Shareholder and Concurrent Repurchase of Shares by Navigator Gas

Written by Customer Service on June 12, 2024. Posted in Public Companies.

LONDON, June 12, 2024 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (NYSE: NVGS) (“Navigator Gas,” the “Company,” “we,” or “our”) announced today the upsize and pricing of the previously announced public offering (the “Secondary Offering”) of a total of 7,000,000 shares of the Company’s common stock (the “Offered Shares”) by BW Group Limited, as the selling shareholder of the Company (the “Selling Shareholder”), at a public offering price of $15.00 per share. The Secondary Offering is expected to close on or about June 13, 2024, subject to customary closing conditions. The Company is not offering any shares of its common stock in the Secondary Offering and will not receive any proceeds from the sale of its shares of common stock in the Secondary Offering. In addition, as previously announced, the Company intends to purchase from the...

Invesco Ltd: Form 8.3 – Quanex building Products Corporation

Written by Customer Service on June 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Quanex Building Products Corporation (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable...

Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Written by Customer Service on June 12, 2024. Posted in Public Companies.

– Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications – – Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® – ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024 in Park City, Utah. These presentations highlighted the versatility and potential advantages of suprachoroidal administration of therapeutics in treating retinal diseases. “Clearside is leading the way in suprachoroidal delivery, including having the only FDA approved product...

Vertex Acquires Artificial Intelligence Tax Capabilities from Ryan, LLC

Written by Customer Service on June 12, 2024. Posted in Mergers And Acquisitions.

Acquisition Streamlines Tax Categorization with Generative AI KING OF PRUSSIA, Pa., June 12, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today the acquisition of tax-specific AI capabilities from Ryan, LLC, an award-winning tax services and software firm, designed to more effectively manage the complexity of tax mapping. Financial terms of the transaction were not disclosed. The categorization of products for taxability is a manual and time-consuming process that is critical for achieving enhanced tax accuracy, especially for high-volume businesses that must manage indirect tax compliance globally, at scale. The acquisition will accelerate Vertex’s AI innovation strategy to help global companies manage tax complexity with greater speed...

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection

Written by Customer Service on June 12, 2024. Posted in Public Companies.

STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead candidate drug BSG005 in patients with invasive fungal infections in India. Biosergen and its partner, Alkem Laboratories Limited, have received approval of the Clinical Trial Application (CTA) and an important import license in India. With the approval and import license in place, the first patient trial of BSG005 can now be initiated. The clinical trial is designed to enroll patients suffering from severe fungal infections, including mucormycosis (Black fungus), aspergillosis, and candidiasis. The focus of the trial is on patient populations intolerant or resistant to amphotericin B, the current last-resort treatment for severe invasive fungal...

Atour Lifestyle Holdings Limited Announces Pricing of Registered Secondary Offering of American Depositary Shares by Legend Capital

Written by Customer Service on June 12, 2024. Posted in Public Companies.

SHANGHAI, China, June 12, 2024 (GLOBE NEWSWIRE) — Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced the pricing of a registered secondary underwritten offering by entities affiliated with Legend Capital (“Legend Capital”) of an aggregate of 10,000,000 American depositary shares (the “ADSs” and such offering, the “Secondary Offering”), each ADS representing three Class A ordinary shares of par value US$0.0001 each of the Company, at an offering price of US$16.90 per ADS. The underwriters in the Secondary Offering will have a 30-day option to purchase up to 1,500,000 additional ADSs from Legend Capital. The Company will not receive any proceeds from the sale of the ADSs by Legend Capital. The gross proceeds of the Secondary Offering to...

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

Written by Customer Service on June 12, 2024. Posted in Public Companies.

Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE) — OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor types. OBI plans to enroll patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer (GC), and other potential cancers. The objective of the trial is to verify the safety, pharmacokinetics, and preliminary efficacy profile of OBI-992 in these patient populations. OBI Pharma’s Chief Medical Officer, M. Wayne Saville, M.D., noted, “Based on our preclinical data, OBI-992...

MAY VOLUMES: BOTH FREIGHT AND PASSENGER CONTINUED TO GROW

Written by Customer Service on June 12, 2024. Posted in Public Companies.

INVESTOR NEWS no. 44 – 12 June 2024 Ferry – freight: Total volumes in May 2024 were 6.9% above 2023 and up 3.8% adjusted for the addition of Strait of Gibraltar routes in 2024 and closure of the Calais-Tilbury route in 2023. North Sea volumes were just below 2023 partly due to lower automotive volumes following temporary plant closures. Mediterranean volumes were above 2023 driven by higher volumes on all routes. Channel volumes were above 2023 and the Baltic Sea routes likewise continued to grow volumes. For the last twelve months 2024-23, the total transported freight lane metres increased 1.6% to 40.0m from 39.3m in 2023-22. The increase was 0.3% adjusted for the addition of Strait of Gibraltar routes and the Calais-Tilbury route closure. Ferry – passenger: The number of passengers in May 2024 was 49.2% above 2023 and...

Day: June 12, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice